Randomized trial of the adenosine A _2A receptor antagonist istradefylline in advanced PD

Abstract

Istradefylline was generally well tolerated and reduced "off" time as assessed by home diaries. Severity of dyskinesia was unchanged, but "on" time with dyskinesia increased.